CTOs on the Move

Balance Pharmaceuticals

www.balancepharm.com

 
Balance Pharmaceuticals is a Pacific Palisades, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamatrix

Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...

ABS Corporation

ABS Corporation is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flower One

Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket`s, The Clear, and Flower One`s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for the top-performing brands in cannabis. Flower One`s Nevada footprint includes the Company`s flagship facility, a 400,000 square-foot high-tech greenhouse and 55,000 square-foot production facility, as well as a second site with a 25,000 square-foot indoor cultivation facility and commercial kitchen. Flower One has built an industry-leading team focused on becoming the first high-quality, low-cost brand fulfillment partner.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.